publication venue for
- Single-microglia transcriptomic transition network-based prediction and real-world patient data validation identifies ketorolac as a repurposable drug for Alzheimer's disease. 2024
- APOE ε4-associated heterogeneity of neuroimaging biomarkers across the Alzheimer's disease continuum. 2024
- Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer's disease and progressive supranuclear palsy. 2024
- tPA supplementation preserves neurovascular and cognitive function in Tg2576 mice. 2024
- Longitudinal trajectories of Alzheimer's disease CSF biomarkers and blood pressure in cognitively healthy subjects. 2024
- Characterizing molecular and synaptic signatures in mouse models of late-onset Alzheimer's disease independent of amyloid and tau pathology. 2024
- Metabolomics profiling reveals distinct, sex-specific signatures in serum and brain metabolomes in mouse models of Alzheimer's disease. 2024
- Parenchymal CSF fraction is a measure of brain glymphatic clearance and positively associated with amyloid beta deposition on PET. 2024
- Advancing specificity in delirium: The delirium subtyping initiative. 2023
- Catalyzing dementia care through the learning health system and consumer health information technology. 2023
- Association of liver fibrosis with cognitive test performance and brain imaging parameters in the UK Biobank study. 2022
- CRISPR/Cas9 screen in human iPSC-derived cortical neurons identifies NEK6 as a novel disease modifier of C9orf72 poly(PR) toxicity.. 19. 2022
- The landscape of metabolic brain alterations in Alzheimer's disease. 2022
- Predictive metabolic networks reveal sex- and APOE genotype-specific metabolic signatures and drivers for precision medicine in Alzheimer's disease.. 19. 2022
- Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. 2021
- Patterns of tau pathology identified with 18 F-MK-6240 PET imaging.. 18. 2021
- Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression. 2020
- Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.. 17. 2020
- Individualized clinical management of patients at risk for Alzheimer's dementia.. 15. 2019
- Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.. 15. 2018
- Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.. 14. 2018
- Regional vulnerability in Alzheimer's disease: The role of cell-autonomous and transneuronal processes.. 14. 2018
- Metabolic network failures in Alzheimer's disease: A biochemical road map.. 13. 2017
- Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol.. 11. 2015
- A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.. 11. 2014
- APOE ε4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role?. 10. 2014
- The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity.. 11. 2014
- Widespread white matter degeneration preceding the onset of dementia.. 11. 2014
- The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. 10. 2014
- Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation.. 11. 2013
- Predictors for cognitive decline in patients with confluent white matter hyperintensities.. 8. 2012
- Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment.. 7. 2011
- Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer's disease patients.. 7. 2011
- Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia.. 7. 2011
- Transcranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's disease.. 7. 2011
- Vascular dysfunction-The disregarded partner of Alzheimer's disease.. 15. 2019
- The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach.. 14. 2018
- Potential roles of digital technologies in clinical trials.. 13. 2017
- Epigenetics of dementia remains unraveled in Latin American and Caribbean populations: A call for collaborative efforts. 2024
- Recommendations for a new perioperative cognitive impairment nomenclature. 2019
- The Vascular Impairment of Cognition Classification Consensus Study. 2016
- Preventing dementia by preventing stroke: The Berlin Manifesto. 2019
- Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. 2016
- Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. 2014
- Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. 2014
- The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). 2012
- Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference. 2024
- Novel avenues of tau research. 2024
- Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy. 2023
- Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias. 2022
- Military-related risk factors for dementia. 2018